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bronchoscopy at supine position
I read with interest a recent article in Respiratory
Medicine ( January 2001) by Meahjee et al. reporting the
in£uence of patient position on desaturation during
bronchoscopy .They had asserted that whether a more
signi¢cant trend would occur in patients with hypoxic
COPD remains undetermined. Our results on this
subject had been presented in Barcelona in 1996 (1).We
had performed bronchoscopy in patients with airways
obstruction and / or hypoxi. All patients had showed a
decrease at oxygen saturation. Patients having SaO2 less
than 92% and FEV1 less than 70% had revealed a more
prominent desaturation, (respectively11?4% vs. 6?85% in
hypoxemic patients and11?58% vs. 3?75% in patients with
obstruction). The position of the patient did not a¡ect
oxygen desaturation in groups with higher than 70% of
baseline FEV1. Patients with lower FEV1 had
demonstrated more desaturation at the supine position
than those at the semi-recumbent position (14?46% of
desaturation at supine position vs. 8?7% at the semi-
recumbent position). Similarly, the oxygen desatura-
tion during ¢bre-optic bronchoscopy had been more
signi¢cant in hypoxic COPD (at the supine position
14?6% of desaturation vs. 8?2% at the semi-recumbent
position).
It was reported that desaturation showed correc-
tion with oxygen supplementation. But approximately
11% of desaturation may be hazardous in patients
with COPD. Therefore since 1996 we have applied
oxygen supplementation during bronchoscopy, especially
in patients with obstruction and hypoxi. In our
opinion,measurementof FEV1and SaO2beforebroncho-
scopy may help to estimate desaturation during
bronchoscopy.
Consequently, we have advised that patients with air-
way obstruction and hypoxemia must receive oxygen at
all stages of bronchoscopic procedures (pre, during and
post) and must be prefer semi-recumbent position in
such patients.
A.N.MIRCI,
Director of Chest Diseases Department,
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Re: Evaluation of an inspiratorymuscle
trainerinhealthyhumans (RespirMed 95:
526^531): Critique of Hart et al.
Hart et al. (2001) evaluated an inspiratorymuscle trainer
(Powerbreathes) using 12 healthy subjects in a rando-
mized controlled study using twitch transdiaphragmatic
pressure (Tw Pdi) as the primary outcomemeasure.The
results were published last year in Respiratory Medicine
(95; 526^531).Unfortunately, thepaper containednumer-
ous factual inaccuracies and is, in our opinion, fundamen-
tally £awed.
Powerbreathe research data
The abstract states, ‘No published evidence supports
its [Powerbreathes] e⁄cacy.’ A similar statement,
yetmore explicit, occurs in the Introduction,‘ynodata
exists to support its [Powerbreathes] e⁄cacy.’
Since 1994, ourselves (Caine and Sharpe) as well as Co-
pestake, Donovan, Newall, Romer and Volianitis, have
published PhD theses containing data obtained using
the Powerbreathes inspiratory trainer or pre-manufac-
ture prototypes of the same. To date a considerable
amount of this research has been presented and pub-
lished in numerous formats, (full papers, abstracts, con-
ference proceedings etc.). Whilst most of the research
has yet to be published in full paper format, there are
several manuscripts currently under review or in pre-
paration, thus the notion that, ‘no data exists’ is simply
incorrect.
Powerbreathes loadingmechanism
The authors appear to have misunderstood the funda-
mental mechanism via which Powerbreathes operates.
Powerbreathes is a pressure threshold inspiratorymus-
cle trainer, a pre-determined pressure load must be
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tion otherwise the valve closes, thereby preventing
further inspiratory air£ow.Thus the load remains essen-
tially constant throughout the inspiratory phase of a
training manoeuvre. The authors state that, ‘Once the
valve has opened the resistance to inspiratory air£ow is
minimal’.This is not so, the authorsmay be confusing the
Powerbreatheswith an alternative devicewhich utilizes
solenoid valve technology and does indeed deliver the
training load that they describe (1).
Study design
Subject numbers and unreliability the of Tw Pdi technique
This study utilized 12 subjects (six of whom were
controls). The authors acknowledge the small number
of subjects and the poor reliability of theTw Pdi techni-
que, labelling their data ‘hypothesis generating’. The
authors should have realized from their power analysis
that Tw Pdi is too unreliable to be used in a repeated
measures design with only 6 subjects per group. To
attribute any signi¢cance to these data is inconsistent
with the authors’ own stance which is that the study
would only have been meaningful if it had utilized 234
subjects.
Choice ofexercise protocol
The exercise testusedby the authors (Bruceprotocol) is
commonly used to assess peak or maximal oxygen up-
take. Wetter and Dempsey (2) state that, ‘A universal
¢nding is that _VO2max does not change with speci¢c re-
spiratory muscle training’. However,Wetter and Demp-
sey go on to state that,‘dramatic increases in endurance
performance have been found’. Given this information
the results presented are unsurprising, and we would
suggest that an alternative exercise test (onewhichmea-
sures endurance capacity) would have provided farmore
informative results.
Interpretation of Tw Pdi data
The authors cannot compare their Tw Pdi data to that
obtained using techniques that measure global inspira-
tory pressure or force. Nor can the authors interpret
Tw Pdi data as being indicative of inspiratorymuscle per-
formance per se.The authors fail to acknowledge the im-
portance of the intercostals in developing inspiratory
force. In addition, the authors choose to ignore other
studies that have examined diaphragm strength. For ex-
ample, Suzuki et al. (3) used oesophageal balloons to
measure pleural pressure and thus estimate diaphragm
strength in a training study using a pressure threshold
IMT.They observed a 31% increase in Pdimax following 4
weeks training.Signi¢cance of ¢ndings
The most important new ¢nding of this paper is that
transdiaphragmatic pressure, during a supramaximal
twitch elicited by BAMPS remained unchanged in re-
sponse to 6 weeks of Powerbreathes training. The
authors acknowledge the high between-test variability
associated with the method. However, if we accept this
¢nding as genuinewebelieve that the authors have over-
stated its signi¢cance. Presumably a signi¢cant increase
inTw Pdi could only be caused through hypertrophy of
diaphragmmuscle ¢bres. Jones and Round (4) state that
improvements in strength observedwithin the ¢rst 6^8
weeks of training aremost likely to be a result of altered
neural drive rather than a change in muscle size.There-
fore the lack of signi¢cant change inTw Pdi is less than
surprising.
Neural adaptations (recruitment of a larger propor-
tion of available motor units or altered stimulation pat-
terns) do give rise to a genuine increase in muscular
strength. Further, it has been shown that an increase in
diaphragmatic strength will have genuine e¡ects on re-
spiratory sensation during exercise (5). Therefore,
although Powerbreathes training is unlikely to causes
substantial diaphragmatic hypertrophy (within 6 weeks)
it is wrong to state that using the device cannot be ben-
e¢cial.
The authors interpret their limited data as if it were
obtained from a series of de¢nitive studies.The introduc-
tion contains the statement.‘The continued sale and use
of the Powerbreathes device is not justi¢edby our data.’
TheDiscussion reinforces this position,‘ywereject the
concept that use, by healthy subjects, of the Power-
breathes device is bene¢cialyChest physicians should
not advise purchase of the Powerbreathes unless
furtherdata become available.’ The studydesign is £awed
and the scope limited; the data presented do not justify
the unequivocal conclusions or assertive interpretations
made by the authors.
Wider implications
The authors have failed to realize that Powerbreathes is
used in a wide range of applications: medical; sporting;
occupational and recreational. Many users report re-
duced levels of dyspnoea or respiratory discomfort fol-
lowing a period of Powerbreathes training. Hart et al.
made no measure of exertional breathlessness or re-
spiratorydiscomfort.What ismore distressing is the fact
that these data be used to refute the bene¢ts of Power-
breathes training without discrimination. Are the
authors suggesting that their data are transferable to
breathing apparatus users, high altitude climbers, time
trial cyclists, rugbyplayers, asthmatics, cystic ¢brosis pa-
tients, singers etc.? Their experimental protocol simply
does not permit comment on the wider bene¢ts of
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groups di¡ering from that studied.
Regulation and conditions of sale
We fail to see what relevance Powerbreathes commer-
cial operations have upon this study. However, we feel
the points raised by the authors in this regard should be
addressed. Within the Signi¢cance of the Findings sec-
tion the authors state that ‘ythe device [Power-
breathes] is sold direct to the public without any form
of regulation’.This statement is not true, Powerbreathes
is CE marked as a Class I medical device. To qualify for
certi¢cation, this European safety directive requires evi-
dence that the product is su⁄ciently well designed and
built that it is ¢t for the purpose for which it is sold and
that reasonable precautions are taken to protect the
user against injury while the product is being used. In ad-
dition, Powerbreathe is sold in accordancewithThe Brit-
ish Codes of Advertising and Sales Promotion as
regulated by the Advertising Standards Association.The
O⁄ce of Fair Trading also regulates the consumer pro-
duct market within the UK. In the 5 years that Power-
breathes has been commercially available there have
been no complaintsmade regardingmisleading advertis-
ingorproduct literature.Furthermore, IMTTechnologies
Ltd, the company that ¢rst commercialized Power-
breathes, o¡ered a 30-day ‘no-quibble money-back’
guarantee on every unit sold; this far exceeded any stat-
utory requirement. The National Asthma Campaign’s
Medical Advisory Committee scrutinized Power-
breathe’s e⁄cacy before approving a series of advertise-
ments in their Asthma News publication. In addition,
several sports governing bodies have endorsed the pro-
duct as have themedical charity Research into Ageing.
M.CAINE* AND G. SHARPEw
*Programme Director, SportsTechnology,
Loughborough University, Loughborough,
UK, w Lecturer, Exercise Physiology,
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Sir,
Re: Evaluation of an inspiratorymuscle
trainerinhealthyhumans (RespirMed 95:
526^531). A reply to Drs Caine and
Sharpe
We thank Drs Caine and Sharpe for their interest in our
paper. Some of their comments overlap with the points
made by Dr McConnell and her co-workers and I do not
propose to reply to them all individually. Nevertheless
there are some points that I wish to pick out.
First,DrsCaine and Sharpe state thatdata concerning
the Powerbreathe has been published in seven PhD the-
ses since 1994. To my mind this begs the question as to
why these data have notbeen submitted for peer review
publication.Clearly, if this group had thought it appropri-
ate to submit their data for publication then we (and
other readers) would have been able to assess their data
on its own merits as indeed our data can be so judged.
Drs Caine and Sharpe state that a considerable amount
of their research has been presented and published in
formats including that of full papers.We were unable to
¢nd any papers using on-line literature searching at the
time of writing and we are puzzled as to why Drs Caine
and Sharpe do not refer to any of these papers in their
reply.
We also dispute the suggestion that we are un-
familiar with how the device works. Essentially the
subject has to generate a preset pressure below which
no air£ow occurs. Above this pressure resistance to air-
£ow is greatly reduced and air£ow is broadly propor-
tional to the pressure excess generated by the
inspiratory muscles above this threshold.The device has
been described elsewhere (1) as a threshold loader.We
didnot conduct an in vitro study of the devices character-
istics andwould be interested to know if DrMcConnell’s
group have done so.
Further on in their critique, the authors say that our
failure to ¢nd a bene¢t in healthy subjects does not pre-
clude a bene¢t in patients with respiratory disease (or
high altitude climbers, athletes, singers etc). Our point
of view on this would be that as with healthy subjects
there are no published data to address the utility of the
advice in these groups and that, other thingsbeing equal,
it is probably wiser to extrapolate the data from normal
subjects than to speculate on the basis of no data at all.
